Literature DB >> 10693156

Putamen mitochondrial energy metabolism is highly correlated to emotional and intellectual impairment in schizophrenics.

J A Prince1, J Harro, K Blennow, C G Gottfries, L Oreland.   

Abstract

In a recent study, we demonstrated that cytochrome-c oxidase (COX), an indicator of neuronal activity, is increased in several brain regions from chronic, medicated schizophrenics. In the present study, to address the functional significance of those findings, we have measured COX activity in a group of schizophrenics in whom antemortem geriatric measures of motor, intellectual, and emotional impairment had been assessed. COX activity in the putamen was strongly negatively correlated with emotional (r = -.76; p < .005) and intellectual impairment (r = -0.76; p < .005), but not with motor impairment (r = 0.01). No significant correlations could be found in the frontal cortex, thalamus, caudate nucleus, globus pallidus, mesencephalon, or nucleus accumbens. Dopamine D2 receptor density in the putamen, measured with [3H]raclopride, was elevated in schizophrenics as compared to controls, as were Kd values. In contrast to COX activity, D2 receptor binding was moderately, but significantly positively correlated with intellectual impairment (r = 0.64; p < .05) but not with motor impairment. Results expose a unique anomaly in the effects of neuroleptics in terms of increasing neuronal signaling in the putamen, which may underlie a reversal of cognitive deficits in schizophrenics, while at the same time, elevating D2 receptor density that seems to be detrimental.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10693156     DOI: 10.1016/S0893-133X(99)00111-6

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  14 in total

Review 1.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 2.  Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.

Authors:  L Holper; D Ben-Shachar; J J Mann
Journal:  Neuropsychopharmacology       Date:  2018-05-16       Impact factor: 7.853

3.  Elevated Excitatory Input to the Nucleus Accumbens in Schizophrenia: A Postmortem Ultrastructural Study.

Authors:  Lesley A McCollum; Courtney K Walker; Joy K Roche; Rosalinda C Roberts
Journal:  Schizophr Bull       Date:  2015-03-27       Impact factor: 9.306

Review 4.  Postmortem studies on mitochondria in schizophrenia.

Authors:  Rosalinda C Roberts
Journal:  Schizophr Res       Date:  2017-02-09       Impact factor: 4.939

5.  Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response.

Authors:  Shahza M Somerville; Adrienne C Lahti; Robert R Conley; Rosalinda C Roberts
Journal:  Synapse       Date:  2011-03       Impact factor: 2.562

6.  Regional patterns and clinical correlates of basal ganglia morphology in non-medicated schizophrenia.

Authors:  Martina Ballmaier; Florian Schlagenhauf; Arthur W Toga; Jürgen Gallinat; Michael Koslowski; Michele Zoli; Cornelius Hojatkashani; Katherine L Narr; Andreas Heinz
Journal:  Schizophr Res       Date:  2008-09-24       Impact factor: 4.939

7.  The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

Review 8.  Mitochondria in neuroplasticity and neurological disorders.

Authors:  Mark P Mattson; Marc Gleichmann; Aiwu Cheng
Journal:  Neuron       Date:  2008-12-10       Impact factor: 17.173

9.  Mitochondrial Dysfunction and Chronic Disease: Treatment With Natural Supplements.

Authors:  Garth L Nicolson
Journal:  Integr Med (Encinitas)       Date:  2014-08

Review 10.  Mitochondrial involvement in psychiatric disorders.

Authors:  Ling Shao; Maureen V Martin; Stanley J Watson; Alan Schatzberg; Huda Akil; Richard M Myers; Edward G Jones; William E Bunney; Marquis P Vawter
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.